A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility
暂无分享,去创建一个
H. P. Sørensen | Mingdong Huang | P. Andreasen | Baoyu Zhao | J. Nielsen | J. Jensen | A. Christensen | K. Jensen | Peng Xu | K. K. Sørensen | Longguang Jiang | N. C. Nielsen | M. Hosseini | Berit Paaske | Zhuo Liu | T. Kromann-Hansen
[1] F. Mulder,et al. Bicyclic Peptide Inhibitor of Urokinase‐Type Plasminogen Activator: Mode of Action , 2013, Chembiochem : a European journal of chemical biology.
[2] P. Leiman,et al. Bicyclic peptide ligands pulled out of cysteine-rich peptide libraries. , 2013, Journal of the American Chemical Society.
[3] Giuseppe Zanotti,et al. Bicyclic peptide inhibitor reveals large contact interface with a protease target. , 2012, ACS chemical biology.
[4] Mingdong Huang,et al. Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs , 2011, Molecular Pharmacology.
[5] C. Weydert,et al. The binding mechanism of a peptidic cyclic serine protease inhibitor. , 2011, Journal of molecular biology.
[6] F. Poulsen,et al. Random coil chemical shift for intrinsically disordered proteins: effects of temperature and pH , 2011, Journal of biomolecular NMR.
[7] B. Furie,et al. Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1* , 2011, The Journal of Biological Chemistry.
[8] G. Salvesen,et al. Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.
[9] Michele Bernasconi,et al. Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model , 2010, PloS one.
[10] Hanne Mørck Nielsen,et al. Challenges in Delivery of Biopharmaceuticals; the Need for Advanced Delivery Systems , 2009 .
[11] Knud J. Jensen,et al. Peptide and protein design for biopharmaceutical applications , 2009 .
[12] H. Kessler,et al. Design of Cyclic Peptides , 2009 .
[13] G. Winter,et al. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. , 2009, Nature chemical biology.
[14] A. Bax,et al. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts , 2009, Journal of biomolecular NMR.
[15] P. Andreasen,et al. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. , 2008, The Biochemical journal.
[16] C. Yuan,et al. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. , 2007, Journal of structural biology.
[17] A. Brunger. Version 1.2 of the Crystallography and NMR system , 2007, Nature Protocols.
[18] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[19] X. Puente,et al. Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.
[20] L. Hedstrom. Serine protease mechanism and specificity. , 2002, Chemical reviews.
[21] Dirk Labudde,et al. A software tool for the prediction of Xaa-Pro peptide bond conformations in proteins based on 13C chemical shift statistics , 2002, Journal of biomolecular NMR.
[22] P. Andreasen,et al. The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.
[23] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[24] C. Ponting,et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. , 1995, Structure.
[25] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[26] K. Danø,et al. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.
[27] B. Furie,et al. The molecular basis of blood coagulation , 1988, Cell.
[28] K. Wüthrich. NMR of proteins and nucleic acids , 1988 .
[29] X. Puente,et al. Protease Genomics and the Cancer Degradome , 2008 .
[30] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[31] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[32] E. Ruoslahti,et al. Peptides in cell adhesion research. , 1994, Methods in enzymology.
[33] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.